<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82158">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723748</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-491-12</org_study_id>
    <secondary_id>35197</secondary_id>
    <nct_id>NCT01723748</nct_id>
  </id_info>
  <brief_title>Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects</brief_title>
  <official_title>Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acromegaly is a rare disease usually caused by a benign growth hormone (GH) producing
      pituitary adenoma. In case of inadequate disease control, the condition is associated with
      significant morbidity and approximately a doubling  of mortality compared to the background
      population. Medical treatment with somatostatin analogues (SA) has been employed for about
      20 years and is a well-established treatment in cases where surgery is impossible or
      inadequate. The treatment with SA still leaves some questions unanswered. Firstly, SA
      treatment often results in a concomitant suppression of the insulin secretion, which might
      lead to clinically significant glucose intolerance. Secondly, the traditional evaluation of
      disease activity by measuring circulating levels of GH and total IGF-I is not reliable
      enough

      Hypotheses: Treatment of acromegaly with SA versus surgery alone is associated with:

        -  Glucose intolerance despite normalized insulin sensitivity

        -  Modified peripheral GH activity in peripheral target organs assessed on molecular
           endpoints
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>glucose tolerance, including AUC (area under the curve)insulin</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>concentration of interstitial bioactive IGF-I as well as total IGF-I, IGFBP and insulin</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>GH, and insulin signal transduction in muscle and fat biopsies.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acromegaly</condition>
  <condition>Somatostatin</condition>
  <condition>Metabolism</condition>
  <condition>Signal Transduction</condition>
  <arm_group>
    <arm_group_label>surgery treated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients with well-controlled acromegaly for at least 6 months after surgery alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SA treated</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 patients with well-controlled acromegaly for at least 6 months after SA treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers without Acromegaly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GH</intervention_name>
    <description>iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.</description>
    <arm_group_label>surgery treated</arm_group_label>
    <arm_group_label>SA treated</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years

          -  treated acromegaly

          -  considered suitable

        Exclusion Criteria:

          -  pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Otto L Joergensen, prof. dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jakob Dal, phd student</last_name>
    <phone>+45 61394231</phone>
    <email>jakob.dal@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakob Dal, phd student</last_name>
      <phone>+45 61394231</phone>
      <email>jakob.dal@dadlnet.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acromegaly</keyword>
  <keyword>Somatostatin treatment</keyword>
  <keyword>metabolic effect</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
